Envoy Medical (COCH) Liabilities and Shareholders Equity (2021 - 2026)

Envoy Medical (COCH) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $29.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 187.16% year-over-year to $29.8 million; the trailing twelve-month figure through Mar 2026 stood at $56.5 million (up 48.36% YoY), and the FY2025 full-year result was $8.6 million, down 25.83% from the prior year.
• Liabilities and Shareholders Equity rose to $29.8 million in Q1 2026, from $8.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $427.8 million in Q3 2022 to a low of $2.6 million in Q4 2022.
• A 5-year average of $90.4 million and a median of $10.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity sank 99.4% in 2022 and soared 223.59% in 2023, its largest moves.
• Tracing COCH's Liabilities and Shareholders Equity over 5 years: stood at $2.6 million in 2022, then soared by 223.59% to $8.3 million in 2023, then surged by 39.5% to $11.5 million in 2024, then fell by 25.83% to $8.6 million in 2025, then surged by 248.47% to $29.8 million in 2026.
• Business Quant data shows COCH's Liabilities and Shareholders Equity at $29.8 million in Q1 2026, $8.6 million in Q4 2025, and $8.2 million in Q3 2025.